Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial
Authors:
- Francesco P. SchenaFSFrancesco P. Schena
- Michael D. PascoeMPMichael D. Pascoe
- Josefina AlberuJAJosefina Alberu
- Maria del Carmen RialMRMaria del Carmen Rial
- Rainer OberbauerRORainer Oberbauer
- Daniel C. BrennanDBDaniel C. Brennan
- Josep M. CampistolJCJosep M. Campistol
- Lorraine RacusenLRLorraine Racusen
- Martin S. PolinskyMPMartin S. Polinsky
- Robert Goldberg-AlbertsRGRobert Goldberg-Alberts
- Huihua LiHLHuihua Li
- Joseph ScarolaJSJoseph Scarola
Top Cited Papers
- 27 January 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 87 (2) , 233-242
Abstract
The efficacy and safety of converting maintenance renal transplant recipients from calcineurin inhibitors (CNIs) to sirolimus (SRL) was evaluated. Eight hundred thirty renal allograft recipients, 6 to 120 months posttransplant and receiving cyclosporine or tacrolimus, were randomly assigned to continue CNI (n=275) or convert from CNI to SRL (n=555). Primary endpoints were calculated Nankivell glomerular filtration rate (GFR; stratified at baseline: 20–40 vs. >40 mL/min) and the cumulative rates of biopsy-confirmed acute rejection (BCAR), graft loss, or death at 12 months. Enrollment in the 20 to 40 mL/min stratum was halted prematurely because of a higher incidence of safety endpoints in the SRL conversion arm. Intent-to-treat analyses at 12 and 24 months showed no significant treatment difference in GFR in the baseline GFR more than 40 mL/min stratum. On-therapy analysis of this cohort showed significantly higher GFR at 12 and 24 months after SRL conversion. Rates of BCAR, graft survival, and patient survival were similar between groups. Median urinary protein-to-creatinine ratios (UPr/Cr) were similar at baseline but increased significantly after SRL conversion. Malignancy rates were significantly lower at 12 and 24 months after SRL conversion. Post hoc analyses identified a subgroup with baseline GFR more than 40 mL/min and UPr/Cr less than or equal to 0.11, whose risk-benefit profile was more favorable after conversion than that for the overall SRL conversion cohort. At 2 years, SRL conversion among patients with baseline GFR more than 40 mL/min was associated with excellent patient and graft survival, no difference in BCAR, increased urinary protein excretion, and a lower incidence of malignancy compared with CNI continuation. Superior renal function was observed among patients who remained on SRL through 12 to 24 months, particularly in the subgroup of patients with baseline GFR more than 40 mL/min and UPr/Cr less than or equal to 0.11.Keywords
This publication has 16 references indexed in Scilit:
- Sirolimus Therapy after Early Cyclosporine Withdrawal Reduces the Risk for Cancer in Adult Renal TransplantationJournal of the American Society of Nephrology, 2006
- Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantationTransplant International, 2004
- Long-Term Renal Allograft Survival: Have we Made Significant Progress or is it Time to Rethink our Analytic and Therapeutic Strategies?American Journal of Transplantation, 2004
- Sirolimus-Based Therapy Following Early Cyclosporine Withdrawal Provides Significantly Improved Renal Histology and Function at 3 YearsAmerican Journal of Transplantation, 2004
- The Natural History of Chronic Allograft NephropathyNew England Journal of Medicine, 2003
- Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination1, 2Transplantation, 2002
- Chronic allograft nephropathy: An updateKidney International, 1999
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progressionClinical Biochemistry, 1998
- Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycleJournal of Cellular Physiology, 1993